Neutralization of tumor necrosis factor-related apoptosis-inducing ligand reduces spinal cord injury damage in mice

Giuseppina Cantarella1, Giulia Di Benedetto, Mimmo Scollo

  • 1Department of Experimental and Clinical Pharmacology, University of Catania School of Medicine, Catania, Italy.

Insights

Targeting tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) improved recovery after spinal cord injury (SCI) by reducing inflammation and cell death. TRAIL and GITRL pathways synergize in SCI damage.

Area of Science:

  • Neuroscience
  • Immunology
  • Cell Biology

Background:

  • Spinal cord injury (SCI) leads to significant disability, with outcomes influenced by damage extent and proapoptotic cytokines.
  • Tumor necrosis factor receptor superfamily members and their ligands are upregulated post-SCI, contributing to damage.

Purpose of the Study:

  • Investigate the role of the proapoptotic cytokine tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in mouse SCI.
  • Explore the interaction between TRAIL and glucocorticoid-induced TNF receptor superfamily-related protein (GITR) pathways in SCI.

Main Methods:

  • Utilized mouse models of SCI, immunostaining, western blotting, and immunoneutralization of TRAIL.
  • Analyzed inflammatory molecules, apoptotic markers, and signaling pathways.
  • Examined GITR and GITRL expression in wild-type and GITR-deficient mice.

Main Results:

  • SCI induced significant trauma, inflammation, and apoptosis, with TRAIL and its receptor DR5 present in the perilesional area.
  • Anti-TRAIL treatment improved functional recovery, reduced cell apoptosis, and modulated inflammatory markers and signaling pathways.
  • SCI upregulated GITR and GITRL; anti-TRAIL treatment prevented this, and GITR deficiency reduced TRAIL/DR5 expression, indicating pathway synergy.

Conclusions:

  • TRAIL plays a critical role in SCI-induced inflammatory damage and apoptosis.
  • TRAIL and GITRL pathways synergistically contribute to SCI pathogenesis.
  • Targeting TRAIL and associated pathways offers a potential therapeutic strategy for SCI treatment.

Related Concept Videos